Related Experiment Videos
[Does statin therapy reduce the risk of stroke? A meta-analysis]
M Sirol1, A Bouzamondo, P Sanchez
1Service de Pharmacologie, Hôpital Pitié-Salpêtrière, 47, boulevard de l'Hôpital, 75651 Paris Cedex 13.
Insights
Statins significantly reduce stroke risk by 24% in patients with coronary heart disease. This meta-analysis confirms statin benefits for cardiovascular mortality and myocardial infarction, showing consistent stroke prevention across various risk levels.
Area of Science:
- Cardiology
- Pharmacology
- Clinical Trials
Context:
- HMG-CoA reductase inhibitors (statins) are proven to reduce cardiovascular mortality by 30%.
- The specific impact of statins on stroke prevention requires further determination.
- Existing clinical trials provide data on statin use in cardiovascular disease prevention.
Purpose:
- To review controlled clinical trials comparing statins versus placebo.
- To determine the specific benefit of statins on stroke prevention.
- To analyze the efficacy of statins in primary and secondary cardiovascular disease prevention.
Summary:
- A meta-analysis of 13 trials with over 32,000 patients showed statin treatment reduced stroke risk by 24% (RRR).
- Statins also reduced cardiovascular mortality by 25% and myocardial infarction by 34% without heterogeneity.
- Stroke reduction was 25% in secondary prevention and 15% in primary prevention, consistent across baseline risks.
Impact:
- Statin treatment demonstrates preventive efficacy against stroke in middle-aged patients with coronary heart disease.
- Results support the use of statins for stroke risk reduction in this population.
- Further research is needed to clarify mechanisms and efficacy in higher-risk populations, such as the elderly.
Abstract:
Large scale clinical trials have clearly demonstrated that the HMG-CoA reductase inhibitors (statins) reduce cardiovascular mortality by about 30%. The specific benefit on stroke prevention remains however to be determined. We reviewed all controlled clinical trials comparing statins versus placebo in primary and secondary prevention of cardiovascular disease. We identified 13 studies including 4S, CARE, WOSCOPS and LIPID. More than 32000 patients were randomized. The meta-analysis was performed using relative risk as treatment effect parameter. Statin treatment induced a significant relative risk reduction (RRR) of 24% (95% CI [12%-34%]) for stroke (2.1% vs 2.8%). RRR achieved 25% (95% CI [17%-32%]) for cardiovascular mortality and 34% (95% CI [30%-38%]) for myocardial infarction, without heterogeneity between trials. Stroke was reduced by 25% in secondary prevention, and by 15% in primary prevention, without significant heterogeneity between them. RRR of stroke was similar with pravastatin (RRR=0.79, p=0.0038) and with simvastatin (RRR=0.71, p=0.049). The effect model analysis (relationship between annual incidence of events in treated group versus placebo group in each trial) showed that RRR was constant whatever the baseline risk. These results are in favor of a preventive efficacy of statin treatment against stroke in middle aged patients with coronary heart disease. Complementary information will be needed to clarify the mechanism of this beneficial effect and to demonstrate statin efficacy in a population with a higher risk of stroke such as the elderly.